Q-omics provides the consensus-scored EIF4BP3 profile across patient tissues and cancer cell-line models. EIF4BP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EIF4BP3 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, EIF4BP3 RNA expression shows 15,914 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where EIF4BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4BP3 survival associations across molecular data types. EIF4BP3 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4BP3 RNA expression–survival associations across cancer types. High EIF4BP3 expression shows unfavorable associations in ACC, UCEC, LUAD, KICH and KIRP, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EIF4BP3 RNA expression.
This table summarizes EIF4BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4BP3 shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, LUAD, LUSC and CHOL. The KIRC box plot shows higher EIF4BP3 RNA expression in tumor versus normal tissue (log2 FC = +0.742, t-test p < 0.001).
This table shows molecular features associated with EIF4BP3 in patient tissues and cancer cell lines. In patient samples, EIF4BP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
